Faculty, UW School of Medicine and Public Health

Jacques Galipeau, MD

  • Hematology


Dr. Galipeau is a board certified Hematologist with an interest in benign blood disorders, including diagnostic assessment of blood count and hematology laboratory abnormalities, congenital and acquired anemia, and autoimmune blood disorders.

Languages spoken
  • English
University affiliation
  • Department of Medicine

Practice locations

  • UW Carbone Cancer CenterHematology Clinic
    • 600 Highland Ave. / Madison, WI
    • (608) 265-1700
    • Closed now
    • View hours, services and more

Education & credentials

Board certifications
  • Hematology
Medical School
  • Universite de Montreal, Montreal, Quebec, Canada

Hematology and Oncology, Tufts Medical Center, New England Medical Center Hospital, Boston, MA

  • Jewish General Hospital, Montreal, Quebec, Canada
  • Universite de Montreal, Montreal, Quebec, Canada

Research and publications

Dr. Galipeau is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin-Madison, and the inaugural Assistant Dean for Therapeutics Discovery and Development at the UW School of Medicine and Public Health. Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally-recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous, marrow-derived mesenchymal stromal cells for immune disorders, including Crohn's disease and graft versus host disease. He has also developed the field of fusion engineered cytokines, known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is the director of the University of Wisconsin Advanced Cell Therapy Program, whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of cell therapy innovations to improve outcomes for children and adults.